Keller Roberta L, Clyman Ronald I
Department of Pediatrics, University of California, San Francisco 94143, USA.
Pediatrics. 2003 Sep;112(3 Pt 1):583-7. doi: 10.1542/peds.112.3.583.
Although indomethacin produces ductus arteriosus constriction in extremely premature newborns, a recurrent symptomatic patent ductus arteriosus (PDA) frequently develops after the initial course of indomethacin. Currently, there is little information available to determine the effectiveness of a second course of indomethacin in producing permanent ductus closure. The objective of this study was to determine the rate of permanent ductus closure after a second course of indomethacin for a recurrent, symptomatic PDA and to identify the factors associated with permanent ductus closure.
We identified 32 infants (<28 weeks' gestational age) 1) whose ductus was considered to be clinically closed after an initial course of indomethacin and 2) who subsequently developed a symptomatic PDA and received a second course of indomethacin. Clinical variables were evaluated for their association with failure of the second course (defined as surgical ligation after the second course for recurrence of a hemodynamically significant PDA). Data were analyzed by chi(2) analysis, Fisher's exact test, and the Mann-Whitney rank sum test.
After the second course of indomethacin, 56% (18 of 32) of the infants had persistent or recurrent PDA-related symptoms that were considered to be hemodynamically significant. The only significant predictor of failure of the second indomethacin course was the demonstration (by Doppler echocardiogram) of persistent ductus flow within 24 hours of completing the initial indomethacin course. All of the 9 newborns with persistent Doppler ductus flow after the initial indomethacin course failed the second course of indomethacin. In contrast, only 39% (9 of 23) of newborns with absent Doppler flow after the initial indomethacin course failed the second course of indomethacin.
Newborns who are <28 weeks' gestational age and develop a recurrent, symptomatic PDA after completion of an initial indomethacin course rarely respond to multiple courses of indomethacin if there was persistent Doppler evidence of ductus flow after completion of the initial course. Additional indomethacin treatment is unlikely to produce permanent ductus closure.
尽管吲哚美辛可使极早产儿的动脉导管收缩,但在初始吲哚美辛疗程后,有症状的动脉导管未闭(PDA)仍经常复发。目前,关于吲哚美辛第二疗程实现动脉导管永久性闭合有效性的可用信息很少。本研究的目的是确定吲哚美辛第二疗程用于复发性、有症状PDA后动脉导管永久性闭合的发生率,并确定与动脉导管永久性闭合相关的因素。
我们确定了32例(胎龄<28周)婴儿,1)其动脉导管在初始吲哚美辛疗程后被认为临床已闭合,2)随后发生有症状的PDA并接受了吲哚美辛第二疗程。评估临床变量与第二疗程失败(定义为第二疗程后因血流动力学显著的PDA复发而进行手术结扎)之间的关联。数据采用卡方分析、Fisher精确检验和Mann-Whitney秩和检验进行分析。
在吲哚美辛第二疗程后,56%(32例中的18例)的婴儿有持续或复发的与PDA相关的症状,这些症状被认为具有血流动力学意义。吲哚美辛第二疗程失败的唯一显著预测因素是(通过多普勒超声心动图)在完成初始吲哚美辛疗程后24小时内显示有持续的动脉导管血流。初始吲哚美辛疗程后有持续多普勒动脉导管血流的9例新生儿中,所有新生儿的吲哚美辛第二疗程均失败。相比之下,初始吲哚美辛疗程后无多普勒血流的新生儿中,只有39%(23例中的9例)的吲哚美辛第二疗程失败。
胎龄<28周且在完成初始吲哚美辛疗程后发生复发性、有症状PDA的新生儿,如果在初始疗程后有持续的多普勒证据表明动脉导管有血流,则很少对多个吲哚美辛疗程有反应。额外的吲哚美辛治疗不太可能实现动脉导管的永久性闭合。